NetwoRx Bio

Company Overview

Snapshot

Founded in May 2024 by Ori Choshen, NetwoRx Bio operates with 1–10 employees. The company is currently in a Pre-Funding stage, focusing on developing its core technology for immunotherapy.

Business overview

NetwoRx Bio is a Health Tech & Life Sciences company focused on advancing immunotherapy through computational biology and AI. The company decodes complex communication networks within the tumor microenvironment to understand how these interactions influence treatment response and resistance. Utilizing proprietary data from clinical trials and advanced AI analytics, NetwoRx Bio generates a patient-specific metric, the NetwoRx Score, to identify actionable molecular interactions. This score aims to predict responses to immune checkpoint inhibitors, monoclonal antibodies, and small molecule immune modulators, thereby optimizing clinical trial design and enabling precision medicine in oncology. The company serves the biotechnology and pharmaceutical industries within the healthcare and life sciences markets, with a product currently in the clinical trial stage.

Company Intelligence Q&A

When was NetwoRx Bio founded?

NetwoRx Bio was founded in May 2024.

Who are the founders of NetwoRx Bio?

Ori Choshen is a co-founder and CEO of NetwoRx Bio.

What is the primary focus of NetwoRx Bio's technology?

NetwoRx Bio focuses on using computational biology and AI to analyze immune, tumor, and stromal cell interactions within the tumor microenvironment to improve immunotherapy outcomes.

What is the NetwoRx Score?

The NetwoRx Score is a patient-specific metric generated by NetwoRx Bio's AI-driven analytics, designed to identify actionable molecular interactions and predict patient response to immunotherapies.

What markets does NetwoRx Bio target?

NetwoRx Bio targets the biotechnology and pharmaceutical sectors within the healthcare and life sciences markets, with a geographical focus on Europe, Americas, and Asia.